Drugs / Bifidobacterium BSL_PS404
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04029818 | May → Jul 2019 | cardiovascular disorder, low density lipoprotein cholesterol, mild elevation of | Biosearch S.A. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bifidobacterium BSL_PS404 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04029818 ↗ |
| Modality | Other / unclassified | “a bacterium isolated from maternal milk” NCT04029818 ↗ |
| Route | Oral | “Each participant will consume 1 capsule daily at lunch for 8 weeks.” NCT04029818 ↗ |